In addition to what jq1234 pointed out (on the more extensive clinical data available for daclatasvir), there may also have been signs for the very same tox observed in the phase II trial, in the preclinical data of the nuke but not the NS5A. That would strongly suggest which drug is the issue.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.